SIGN UP
LOG IN
News
Innovent Biologics
--
--
0.00%
INNOVENT ANNOUNCES NMPA APPROVAL OF LIMERTINIB, A THIRD-GENERATION EGFR TKI COLLABORATED WITH ASK PHARMA, FOR THE FIRST-LINE TREATMENT OF LUNG CANCER
Reuters · 40m ago
Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting
PR Newswire · 2d ago
Weekly Report: what happened at Innovent Biologics last week (0414-0418)?
Weekly Report · 5d ago
High Growth Tech Stocks In Asia For April 2025
Simply Wall St · 04/15 04:08
Weekly Report: what happened at Innovent Biologics last week (0407-0411)?
Weekly Report · 04/13 22:01
3 Asian Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.6%
Simply Wall St · 04/06 22:04
Weekly Report: what happened at Innovent Biologics last week (0331-0404)?
Weekly Report · 04/06 22:01
Optimistic Investors Push Innovent Biologics, Inc. (HKG:1801) Shares Up 25% But Growth Is Lacking
Simply Wall St · 04/04 22:50
Innovent Biologics Full Year 2024 Earnings: Beats Expectations
Simply Wall St · 03/31 22:56
Weekly Report: what happened at Innovent Biologics last week (0324-0328)?
Weekly Report · 03/30 22:01
Innovent Announces 2024 Annual Results and Business Updates
PR Newswire · 03/26 10:21
INNOVENT BIOLOGICS FY NET INCOME RMB -94.6 MILLION
Reuters · 03/26 10:00
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
PR Newswire · 03/24 00:00
Weekly Report: what happened at Innovent Biologics last week (0317-0321)?
Weekly Report · 03/23 22:01
HUTCHMED AND INNOVENT JOINTLY ANNOUNCE THAT THE FRUSICA-2 PHASE II/III STUDY OF FRUQUINTINIB AND SINTILIMAB COMBINATION HAS MET ITS PRIMARY ENDPOINT IN ADVANCED RENAL CELL CARCINOMA IN CHINA
Reuters · 03/19 00:00
Weekly Report: what happened at Innovent Biologics last week (0310-0314)?
Weekly Report · 03/16 22:01
China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease
PR Newswire · 03/14 08:35
BRIEF-Innovent Is Said To Consider Licensing Partnership For Cancer Drug- Bloomberg News
Reuters · 03/11 03:09
Weekly Report: what happened at Innovent Biologics last week (0303-0307)?
Weekly Report · 03/09 22:01
HEAD-TO-HEAD AGAINST PEMBROLIZUMAB: INNOVENT ANNOUNCES FIRST PATIENT DOSED IN THE FIRST PIVOTAL STUDY OF IBI363 (PD-1/IL-2Α-BIAS BISPECIFIC ANTIBODY FUSION PROTEIN) IN MELANOMA
Reuters · 03/03 00:00
About Innovent Biologics
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sale of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly operates in the domestic and overseas markets.
MoreRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.